Shanghai TheraMabs Bio-technology co., LTD
We are professional supplier in antibodies and fusion proteins,such as Pembrolizumab, Nivolumab, Transtuzumab,etc.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
Purchase
Description
EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
Aflibercept is supplied at a concentration of 40 mg/mL as a sterile, clear, and colorless to pale yellow solution, which contains 10 mM sodium phosphate, 40 mM sodium chloride, 0.03% polysorbate 20, and 5% sucrose, pH 6.2.
Properties
Name | Aflibercept |
CAS NO. | 862111-32-8 |
Type | a recombinant fusion protein |
Source | Human |
Target | VEGF |
Clone | Monoclone |
Molecular Weight | 97 kDa |
Formula | C4318H6788N1164O1304S32 |
Antibody Form | Purified immunoglobulin |
Physical Form | Solution |
Grade Standard | Medicine Grade |
Place of Origin | China (Mainland) |
Storage | -70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light. |
Supply Ability
20 kilogram per year, 1 Gram（Min. Order）.
Material Safety Data Sheet
If you need more information, please contact us.
Certificate Of Analysis
If you need more information, please contact us.
Detail information about the product please refer the website below:
https://en.wikipedia.org/wiki/Aflibercept
